Search

Search Constraints

You searched for: Author/Creator Bertolami, Carmelo

Search Results

1. A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. Issue 1 (8th June 2020)

2. A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. Issue 12 (December 2020)

3. A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. (6th October 2018)

4. Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study. Issue 9 (November 2020)

5. Effectiveness and safety of vedolizumab in biologically naïve patients: A real‐world multi‐centre study. Issue 9 (1st November 2020)

6. SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501. (21st January 2021)

7. SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. Issue 11 (3rd July 2021)

8. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. Issue 2 (19th January 2021)

9. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. Issue 2 (21st February 2020)